Fosmanogepix
Sponsors
Basilea Pharmaceutica International AG Allschwil, Basilea Pharmaceutica
Conditions
CandidemiaCandidiasis, InvasiveFusarium spp.Healthy Adult ParticipantsHepatic ImpairmentInvasive Fungal InfectionsInvasive candidiasisInvasive mold infections caused by Aspergillus spp.
Phase 1
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
CompletedNCT05582187
Start: 2022-10-31End: 2025-10-16Updated: 2025-12-19
A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects
RecruitingNCT07881224
Start: 2026-10-01End: 2027-03-09Target: 42Updated: 2026-10-19
Phase 2
Phase 3
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RecruitingNCT05421858
Start: 2024-12-11End: 2028-01-30Target: 450Updated: 2026-10-19
An interventional efficacy and safety Phase 3 double-blind 2-arm study to investigate IV followed by oral fosmanogepix compared with IV caspofungin followed by oral fluconazole in adult participants with candidemia and/or invasive candidiasis.
RecruitingCTIS2022-500455-23-00
Start: 2024-12-11Target: 157Updated: 2025-11-12
An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds
Not yet recruitingCTIS2024-516216-16-00
Target: 94Updated: 2025-12-01